Degludec insulin is used for adult patients with type 2 diabetes who have poor blood sugar control. It is combined with other oral hypoglycemic drugs on the basis of diet and exercise to improve blood sugar control.
*The following content is generated by AI and is for reference only.
Insulin Degludec and Insulin Detemir are advanced long-acting basal insulin analogs designed to provide stable, prolonged glycemic control for patients with diabetes mellitus. Unlike human insulin, these molecules undergo specific structural modifications to alter their pharmacokinetic profiles, minimizing the risk of hypoglycemia while ensuring consistent blood sugar levels throughout the day and night.
Insulin Detemir is a recombinant DNA-derived analog where a fatty acid side chain (myristic acid) is attached to the B29 position. This modification allows the molecule to bind reversibly to albumin in the subcutaneous tissue and circulation, resulting in a slow, predictable absorption rate that typically lasts up to 24 hours. It is primarily used as a basal therapy in both type 1 and type 2 diabetes to maintain fasting glucose levels.
Insulin Degludec represents a further evolution in basal insulin technology. It forms multi-hexamers upon subcutaneous injection, creating a soluble depot that releases monomers extremely slowly and steadily. This unique mechanism provides an ultra-long duration of action exceeding 42 hours, offering exceptional flexibility in dosing times without compromising efficacy. Both agents are available in pre-filled pens or vials for subcutaneous administration.
While they share similar therapeutic goals, their distinct molecular structures offer different advantages regarding peak activity and dose timing consistency. These analogs have significantly improved the quality of life for diabetic patients by reducing nocturnal hypoglycemia events and simplifying treatment regimens. They are essential components of modern diabetes management strategies, often combined with rapid-acting insulins or oral antidiabetic agents to achieve comprehensive glycemic targets. Continuous monitoring and individualized dosing remain critical for optimizing clinical outcomes with these potent therapies.